In this study, we investigated this heterogeneity, using novel assays to measure activity of tumor-driving signal transduction pathways, e.g., estrogen receptor and PI3K pathways, in multiple samples distributed across the tumor and in metastases. The gene discussed is ESR1; the disease is neoplasm.